Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

1(25.0%)

N/A

1(25.0%)

Phase 2

1(25.0%)

Phase 4

1(25.0%)

4Total

Phase 3(1)

N/A(1)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07402044Not Yet Recruiting

CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)

Role: collaborator

NCT06841614Phase 3Not Yet Recruiting

EBOla Post-Exposure Prophylaxis

Role: collaborator

NCT07146529Not Yet Recruiting

Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis

Role: collaborator

NCT06656611Not ApplicableNot Yet Recruiting

Mobile Outreach Screening of High-Risk Human Papillomavirus Infection in Women with Limited Access to Health Services in Seine-Saint-Denis (greater Paris Area, France)

Role: collaborator

NCT05922735Unknown

Seroprevalence of Monkeypox Infection Among People Living With HIV and PrEP Users

Role: collaborator

NCT04993872Phase 4Unknown

Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF

Role: collaborator

NCT04464278Unknown

Variation in Body Composition on the Fate of Older Subjects During SSR Hospitalization

Role: collaborator

NCT02473328Phase 2Completed

Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients

Role: collaborator

NCT02628340Completed

Comprehensive Analysis of HIV Reservoirs in Chronically Infected HIV-1 Treated Patients

Role: collaborator

All 9 trials loaded